Recent advances in nonalcoholic fatty liver disease metabolomics
Hwi Young Kim
Clin Mol Hepatol. 2021;27(4):553-559.   Published online 2021 Jun 8     DOI: https://doi.org/10.3350/cmh.2021.0127
Citations to this article as recorded by Crossref logo
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults
Ji-Hee Haam, Yun Kyong Lee, Eunkyung Suh, Young-Sang Kim
Diagnostics.2022; 12(5): 1199.     CrossRef
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
World Journal of Clinical Pediatrics.2022; 11(3): 221.     CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
Hepatology Research.2022;[Epub]     CrossRef
Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
Yanbo Feng, Han Li, Cong Chen, Hao Lin, Guangyu Xu, He Li, Chunmei Wang, Jianguang Chen, Jinghui Sun
Frontiers in Pharmacology.2021;[Epub]     CrossRef